There are few effective treatments for metastatic melanoma. Checkpoint kinase 1 (Chk1) inhibitors are being trialled for their efficacy in enhancing conventional chemotherapeutic agents, but their effectiveness as single agents is not known. We have examined the effectiveness of two novel Chk1 selective inhibitors, AR323 and AR678, in a panel of melanoma cell lines and normal cell types. We demonstrate that these drugs display single-agent activity, with IC50s in the low nanomolar range. The drugs produce cytotoxic effects in cell lines that are most sensitive to these drugs, whereas normal cells are only sensitive to these drugs at the higher concentrations where they have cytostatic activity. The cytotoxic effect is the consequence of inhibition of S-phase Chk1, which drives cells prematurely from late S phase into an aberrant mitosis and results in either failure of cytokinesis or cell death through an apoptotic mechanism. The sensitivity to the Chk1 inhibitors was correlated with the level of endogenous DNA damage indicating replicative stress. Chk1 inhibitors are viable single-agent therapies that target melanoma cells with high levels of endogenous DNA damage. This sensitivity suggests that Chk1 is a critical component of an adaptation to replicative stress in these cells. It also suggests that markers of DNA damage may be useful in identifying the melanomas and potentially other tumour types that are more likely to be sensitive to Chk1 inhibitors as single agents.
INTRODUCTION
Cancer cells have deviated from their normal progenitor cell type to allow them to survive in new growth environments. These changes include the ability to continuously proliferate and avoid apoptosis. Cell-cycle regulators are common targets for mutation and deletion in cancer. In particular, cell cycle checkpoint controls that respond to internal and external stresses such as DNA damage to block cell cycle progression until the stress is resolved or repaired are frequently defective in melanoma. Many tumour suppressors are components of cell cycle checkpoints such as TP53, ATM, p16CDKN2A and BRCA1, 1,2 and in many cases also regulate repair mechanisms. 3 To accommodate checkpoint loss, tumour cells will adapt and utilise compensatory mechanisms and become highly reliant on these for their survival. This dependency can be exploited to selectively destroy the tumour cells without significant toxicity to normal tissue. The targeting of compensatory mechanisms is known as synthetic lethality, where a defective primary mechanism is an intrinsic feature of the cancer cell and inhibition of the compensatory mechanism results in a dramatic loss of viability. 4 Checkpoint kinase 1 (Chk1) is a checkpoint signalling kinase that primarily responds to single-strand DNA that is produced either as an intermediate of specific forms of DNA damage or during stalled replication. 5 Chk1 is activated in response to singlestrand DNA lesions by the apical checkpoint kinase Ataxia Telangiectasia Mutated and Rad3 related. 6 In addition to checkpoint signalling, Chk1 is also involved in DNA repair, regulating the activity of RAD51 and components of the Fanconi anaemia core complex. 7, 8 Chk1 also has an essential role in the unperturbed cell cycle, with knockout of either Chk1 or Ataxia Telangiectasia Mutated and Rad3 related being embryonic-lethal in mice. 6, 9, 10 For normal cell cycling, Chk1 has roles in regulating replication fork activity during S phase, 11, 12 and in regulating entry into mitosis. 13, 14 Chk1 inhibition has been used in combination with conventional chemotherapeutic drugs and radiotherapy to increase the selectivity and efficacy of these treatments. The rationale is that in p53 mutant tumour cells genotoxic therapies promote S-and G2-phase cell cycle checkpoints, which acts as a protective mechanism, reducing the efficacy of these treatments. 15, 16 These checkpoints are commonly dependent on Chk1 and inhibition of Chk1 drives tumour cells into an aberrant mitosis and promotes cell death in these tumours. This has been demonstrated with a range of Chk1 inhibitors in combination with a range of genotoxins, including ionising radiation, gemcitabine and irinotecan. 17, 18 Although Chk1 inhibition alone has been reported to increase DNA damage, 19 there has been little investigation into their potential use in cancer treatment as single agents.
There is a critical need for more effective chemotherapeutic agents for melanoma. The recent success of the selective BRaf inhibitors in the treatment of BRaf V600E melanomas has highlighted the power of targeting specific defects, although rapid onset of resistance to these drugs has been reported. 20 Here we have examined the efficacy of the novel small-molecule inhibitors of Chk1, AR323 and the structurally related AR678, 21 as single agents in melanoma. These are potent selective inhibitors of Chk1 in vitro, with an IC50 of 0.9 nM for AR323. From a panel of 257 kinases tested, the only other kinases significantly inhibited were RSK3 and Mylk, with IC50s of 110 and 50 nM, respectively. 22 Here we have demonstrated these drugs to have single-agent activity against a panel of melanoma cell lines with IC50s in the low nM range. Treatment with these drugs promoted cell cycle arrest and apoptosis as a consequence of Chk1 inhibition in S phase driving cells into a premature and aberrant mitosis. The sensitivity to these drugs correlated with the degree of endogenous DNA damage, a measure of replicative stress in the cells.
RESULTS

Melanoma cells are sensitive to Chk1 inhibitors
The effect of the Chk1 inhibitors AR323 and AR678 on cell viability and cytotoxicity was assessed in a panel of melanoma cell lines across a range of drug concentrations at three time points up to 72 h, or up to 96 h for slower-growing cell lines. Figure 1 shows an example for the highly sensitive cell line A02. Both viability (resazurin) and cytotoxicity (adenylate kinase) assays were used to determine whether reduced viability was associated with increase in cytotoxicity. Both drugs had similar effects on cell viability and cytotoxicity in all the cell lines assessed, as shown for A02 cells (Figure 1a) , and as such only AR323 was used for subsequent experiments. The maximal effects on proliferation were observed from 48 to 72 h after drug addition, whereas the cytotoxic effects continued to increase at 72 h ( Figure 1b) . The cytotoxic effects of the drugs appeared to be selective for the tumour cell lines, with treatment of primary neonatal foreskin fibroblasts (NFF) demonstrating a cytostatic effect at the highest dose of drug used, but little detectible cytotoxicity even after 72 h of drug treatment (Figure 1c ). The data from the resazurin assay, which was a measure of both proliferation and viability, were used to account for both cytostatic and cytotoxic effects of the drugs. AR323 was found to reduce proliferation/viability, with IC50 values ranging from 10 to 600 nM across the panel of melanoma cell lines used (Figure 1d ).
Cytotoxic mechanism of Chk1 inhibitors To investigate the mechanisms by which the Chk1 inhibitors were causing cell death in the melanoma cell lines, a small panel of four cell lines representing the extremes of drug sensitivity were used; A02 and D25 melanoma cell lines were selected as the most sensitive (IC50 of 21 and 27 nM, respectively), with the MM127 melanoma cell line and the primary untransformed NFF cell (IC50 of 4600 and 400 nM, respectively) being the least sensitive. Cell cycle analysis revealed an apparent accumulation of cells in the S phase, with sub-diploid populations also being present in the sensitive cell lines, A02 and D25, but being either absent or less evident in the less-sensitive cell lines. This was apparent by 24 h with 0.1 mM AR323 in the more-sensitive cell lines, but was only detected with 1 mM drug in the less-sensitive lines (Figure 2a, Supplementary Figure S1A Figure S1B ; only SKMEL13 is shown).
To ensure that the effects of the Chk1 inhibitor being examined were a direct consequence of inhibition of Chk1, Chk1 was depleted using short interfering RNA (siRNA). As seen with Chk1 inhibition, depletion of Chk1 in the sensitive A02 cells reduced viability and increased the S-phase population, although a little less effectively than the inhibitor, whereas it had little obvious effect on the insensitive MM127 cells (Figures 2c and d,  Supplementary Figure S2 ). The similarity of the effects in both drug-sensitive and -insensitive cell lines demonstrates that the drug is targeting Chk1 selectively to deliver the cytotoxicity observed in the melanoma cell lines.
Inhibition of Chk1 drives premature entry into mitosis The differential sensitivity of the melanoma cells lines to the Chk1 inhibitors suggested that there may be different levels of activated Chk1 in these lines correlating with their drug sensitivity. Immunoblotting of the panel of melanoma cell lines for the activated Ataxia Telangiectasia Mutated and Rad3 related phosphorylated Ser317 and autophosphorylated Ser296 forms of Chk1 revealed a low level in all cell lines with little apparent difference in levels between lines, suggesting the sensitivity to Chk1 inhibition is not a consequence of increased Chk1 activity (Supplementary Figure S3) . However, the previously reported Sand G2/M-phase roles for Chk1 suggested that the level of activated Chk1 in S and G2 phases may be elevated in cancer cell lines. The presence of activated Chk1 in normal S and G2 phases has not previously been shown. In synchronised HeLa cells, activated Chk1 was observed throughout S (0 --4 h) and G2 (6 --8 h, corresponding to the accumulation of cyclin B1 and the inactive Tyr15 phosphorylated cdk1) phases, and declined as cells entered mitosis (10 h, corresponding to the decline in Tyr15-phosphorylated cdk1; Supplementary Figure S4 ). Activated Chk1 was also observed during S and G2 phases in a panel of melanoma and non-melanoma cell lines assessed using quantitative image analysis of asynchronously growing cells immunostained for the activated Chk1. siRNA depletion of Chk1 demonstrated the specificity of the nuclear immunofluorescent staining for the activated Ser317 phosphorylated Chk1 (pChk1 S317; Supplementary Figure S5A and B). Quantitative imaging of the DNA content and activated Chk1 levels in each cell (assaying 41000 cells for each line) allowed the assignment of cell cycle stage and activated Chk1 content for the population (Supplementary Figure S5C) . The tumour cell lines displayed high proportions of S-and G2-phase cells (40 --80%) that contained pChk1 S317, compared with the primary fibroblasts (NFF), which had o10% of S-phase and o40% of G2-phase cells containing pChk1 S317 (Figure 3a ). The level of activated Chk1 increased with cell cycle stage, although it was below the level induced with the genotoxic drug etoposide ( Figure 3b and Supplementary Figure S5D ). The exception among the tumour cell lines was the Seckel syndrome FO2 cells, which are defective for Ataxia Telangiectasia Mutated and Rad3 related, 23 and had reduced proportions of cells containing activated Chk1 and a reduced response to etoposide (Figure 3a) .
Inhibition of Chk1 with either the Chk1 inhibitor or Chk1 siRNA also drove more rapid entry into mitosis (Supplementary Figure  S6A) . This was not an artefact of the synchrony procedure as rapid entry into mitosis (within 1 --2 h) was also observed in asynchronously growing cells. This was demonstrated by the increased levels of the MEK1 phosphorylated on Thr286 (a marker of cyclin B/cdk1 activity), in the three cell lines including normal NFFs (Supplementary Figures S6B and C) .
Inhibition of Chk1 promotes aberrant mitosis Chk1 inhibition has previously been reported to promote aberrant mitosis. 24, 25 Microscopic examination of Chk1 inhibitor-sensitive Figures 4a and b) . To determine whether the Chk1 inhibitor was causing aberrant mitosis, timelapse microscopy was used to follow the four representative melanoma cells over 72 h of continuous treatment with 1 mM AR323. The outcome of mitosis was quantified as either normal symmetrical division or aberrant division, which often resulted in failed cytokinesis. Quantifying these effects revealed that there was a point of crossover from normal to abnormal mitotic phenotypes after 6 --12 h of drug treatment (Figures 4c and d , and Supplementary Figure S7A) . In all the cell lines, except SKMEL13, almost 100% of the cell population underwent aberrant mitosis, indicating that the majority of cells were undergoing mitosis with only an S-phase complement of DNA. The duration of mitosis was increased in all the drug-treated cell lines from a range of 30 --45 min in controls to 75 --170 min in the drug-treated cells (Supplementary Figure S7B) . The time lag to onset of aberrant mitosis suggested that Chk1 inhibitor during S phase rather than G2 phase was producing the aberrant mitosis. Using synchronised HeLa cells as a model, addition of Chk1 inhibitor to cells in S phase resulted in 80% undergoing an aberrant mitosis (Supplementary Figure S8A) . By contrast, few aberrant mitoses were observed when the drug was added in G2 phase and the majority of mitoses appeared relatively normal (Supplementary Figure S8B) .
The time-lapse imaging also allowed assessment of the timing and mechanism of cell death. In all cases, cells died with an apoptotic phenotype, with evident membrane blebbing after cytoplasmic contraction. This was either during an extended mitosis (Figure 4d ) or after failed mitosis. The majority of the highly drug-sensitive A02 and D25 lines died in mitosis or shortly after exit. When the timing of mitosis and apoptosis was quantified by following the individual fates of 50 less-sensitive SKMEL13 cells after treatment with drug, 15 out of 50 died without undergoing mitosis, and 4 underwent mitosis without dying during the course of the imaging. The remaining cells died either in mitosis or at various times following mitotic exit (Supplementary Figure S9 ). This indicates that aberrant mitosis is not essential for the drug-induced cell death.
S-phase progression is essential for Chk1 inhibitor cytotoxicity The data above indicated that the cytotoxic effect of the Chk1 inhibitor was a consequence of inhibition of Chk1 activity in S phase driving premature exit from S phase and initiating apoptotic cell death. This model suggested that the drug would be ineffective in killing cells blocked from entering S phase. To test this, an SKMEL13 line previously developed with inducible expression of the cdk4/6 inhibitor p16 INK4A (Burgess et al.
26
) was treated with 1 mM AR323 with and without induced p16 expression. Induced p16 INK4A expression arrested cells in G1 phase and prevented apoptosis even after 72 h of drug treatment, whereas un-induced cells were as sensitive as the parental line (Figures 5a and b) .
Markers of endogenous DNA damage correlate with sensitivity to Chk1 inhibitor The presence of activated Chk1 is normally a marker of DNA damage, and its presence in normally proliferating S-and G2-phase melanoma cells suggested that it may be acting as an adaptive measure to accommodate the presence of DNA damage. If this was the case, then cells with elevated levels of endogenous DNA may be more reliant on Chk1 for their continued proliferation and survival and thus more sensitive to inhibition of Chk1. To assess this, whole-cell lysates of asynchronously growing cultures from the panel of melanoma cells were immunoblotted for gH2AX as a marker of DNA damage signalling. Variable levels were found in melanoma cell lines, with the highest levels of each being equivalent to those of etoposide-treated HeLa cells (Figure 6a ). The levels of gH2AX appeared to correlate with sensitivity to AR323, although three sensitive lines, A2058, MM96L and MM200, had levels of gH2AX equivalent to or below the insensitive lines (Figure 6b ). There was a semilinear correlation between gH2AX levels and IC50 values for the cell lines (r 2 ¼ 0.45). The correlation between gH2AX levels and drug sensitivity suggested that drug sensitivity may be related to increased replicative stress. To examine this further, we attempted to convert a drug-insensitive cell line into a drug-sensitive line. MM127 cells were grown in the presence of 0.2 mM hydroxyurea for 2 weeks to increase the potential burden of replicative stress (hydroxyurea lowers deoxyribonucleotide triphosphate pools by inhibiting ribonucleotide reductase). This had only a minor effect on the proliferative ability of the MM127 line (Figure 7a ) but converted the previously Chk1 inhibitor-insensitive line to a highly sensitive line with an IC50 of 30 nM (Figure 7b ). The increased sensitivity correlated with increased gH2AX content (Figure 7c ).
DISCUSSION
Chk1 inhibitors target the cell cycle. This is perhaps not surprising considering that Chk1 functions during S and G2 phases of the unperturbed cell cycle to regulate origin firing and entry into mitosis.
11 --14 Inhibition of Chk1 during S phase has been reported to promote DNA strand breaks and increase gH2AX levels, and Chk1 inhibitors target replicative stress K Brooks et al gH2AX levels increased with replicative stress. 19, 27 Another consequence of Chk1 inhibition in S phase is that the cells undergo aberrant mitosis. 14, 24, 25 The cytotoxic activity of the drugs is dependent on progression into and through S phase, as blocking S-phase progression by increased p16 expression effectively blocked the cytotoxic effect of the drug. Chk1 inhibition promoted premature entry into mitosis and is also likely to contribute to the rapid onset of apoptosis, although the time-lapse studies demonstrated that it is not essential that cells undergo mitosis before triggering apoptosis. The cells that accumulated with S-phase DNA content are cells that prematurely exit S phase without completing replication, and this is the likely cause of the aberrant mitosis observed. In synchronised HeLa cells the aberrant mitosis was only observed with inhibition of S-phase Chk1, and in the melanoma cell lines time-lapse analysis showed that a high proportion of mitoses were aberrant after 6 h drug treatment, resulting from the cells that were in early S phase at the time of drug addition. It was surprising that specific inhibition of Chk1 in G2 phase, which also promoted premature entry into mitosis, had little apparent effect on mitosis. Chk1 regulates progression into mitosis by controlling Cdc25B activity, 14, 28 and Chk1 has also been reported to regulate Aurora B, which likely contributes to lagging chromosomes in mitosis and defective cytokinesis. 29 The resultant aberrant mitosis triggers the spindle assembly checkpoint which is likely to be responsible for the delay in mitosis observed in the cell lines examined here. Activation of the spindle assembly checkpoint is required to prime apoptotic signalling, 30 --33 and Chk1 has also been reported to suppress caspase 2-and caspase 3-dependent apoptotic pathways. 34, 35 Thus, Chk1 inhibition can promote cell death by triggering the mitotic checkpoint and removing suppression of pro-apoptotic caspase activation, which combine to trigger cell death. In the less-sensitive lines such as SKMEL13, where cell death was not tightly associated with mitosis, it is possible that the reduced sensitivity is a consequence of these cells being less sensitive to apoptosis triggered by aberrant mitosis. There is, however, an absolute requirement for transit through S phase for Chk1 inhibitor-induced apoptosis, suggesting the premature S phase exit to be the source of stress inducing apoptosis.
The cytotoxicity of Chk1 inhibitor treatment in the melanoma cell lines and the relative insensitivity of the normal cell types indicate that the Chk1 inhibitors are targeting an S-phase defect in the sensitive cell lines. The correlation between drug sensitivity and higher levels of DNA damage, indicated by the high levels of gH2AX, suggests that Chk1 is necessary for the maintenance of viability in cells replicating DNA with high levels of endogenous DNA damage. This DNA damage is likely to be a marker of replicative stress generated as a consequence of early preneoplastic transformation events such as oncogene activation and/or tumour suppressor inactivation. Such DNA damage is a product of replication fork defects and collapse, and results in a strong DNA damage response. 36 The conversion of the drug-insensitive MM127 cells into highly sensitive cells following conditioning with a low dose of hydroxyurea also increased the levels of gH2AX, demonstrating that sensitivity to Chk1 inhibitor is directly related to the replicative stress of the cells. The melanoma cell lines tolerate these very high levels of replicative stress and proliferate normally. There was no significant correlation between the proliferative rates of the cell lines (doubling times between 24 and 45 h) and the levels of gH2AX. This indicates that the cells have developed adaptive mechanisms to allow them to cope with this high level of endogenous DNA damage without initiating a cell cycle arrest. The p53 pathway is often defective in melanomas, with 6/19 cell lines investigated containing mutant p53, and another three had mutant p14ARF. It is likely that other components of the p53 pathway are defective in these cell lines, and loss of this checkpoint signalling would contribute to making the cells less sensitive to the DNA damage. Adaptation to replicative stress may also oblige cells to become more reliant on Chk1 for replication and survival and thus they are more sensitive to Chk1 inhibition. Therefore, inhibiting Chk1 is an example of synthetic lethal targeting of a tumour-cell-specific dependency. The high levels of endogenous DNA damage in the melanoma cells essentially mimic an externally applied replicative stress. Normal tissue is protected from the cytotoxicity of Chk1 inhibitors by the absence of replicative stress, as demonstrated by the insensitivity of the NFF primary cell line. The cytostatic effect of the Chk1 inhibitors observed at high concentrations in normal cell types is likely to be a consequence of the loss of normal Chk1-dependent replication origin firing, which slows S-phase progression. 11, 12 This may induce p53-dependent suppression of mitotic regulator expression. 37 The results of this study suggest that Chk1 inhibitors may be particularly valuable in treating melanomas, which appear to have an extremely high degree of replicative stress. This appears to be a common feature of melanomas indicated by the large proportion of metastatic melanomas containing high levels of gH2AX. 38 However, it would appear that replicative stress may not be the only determinant of response to Chk1 inhibition, as several cell lines were sensitive to the drugs but had relatively low levels of gH2AX. Alternatively, high levels of replicative stress may exist in these drug-sensitive cell lines, but the signalling pathway may be defective, accounting for the lack of the marker assessed here. This strong association of sensitivity to Chk1 inhibitors with replicative stress suggests that these drugs may be useful single agents in melanoma as well as other tumours with high levels of replicative stress, which can be readily determined using makers of DNA damage response in tumour biopsy samples.
MATERIALS AND METHODS
Cell lines
A panel of 17 melanoma cell lines, A5028, A02, A04, BL, D25, HT144, MM127, MM200, MM329, MM383, MM415, MM576, MM603, MM604, MM96L, SKMEL13 and SKMEL28, Seckel syndrome FO2 cells (gift of Prof Jeggo), HeLa, and primary NFF were assessed in this study. All melanoma cell lines were cultured in RPMI1640 medium (GIBCO, Invitrogen, Mulgrave, Victoria, Australia) containing 10% serum supreme (Biowhittaker, Lonza, Mt Waverley, Victoria, Australia), 25 mM hydroxyethyl piperazineethanesulfonic acid (GIBCO), 1 mM sodium pyruvate (GIBCO) and 2 mM L-glutamine (GIBCO) at 37 1C with 5% CO 2 . p16-Inducible SKMEL13 cells 26 were treated with 5 mM isopropyl b-D-1-thiogalactopyranoside for 24 h to induce p16. FO2, HeLa cells and NFF cells were cultured in Dulbecco's modified Eagle's medium (GIBCO) supplemented with 10% foetal bovine serum (Bovagen, East Keilor, Victoria, Australia), 25 mM hydroxyethyl piperazineethanesulfonic acid (GIBCO), 1 mM sodium pyruvate (GIBCO) and 2 mM PSG antibiotic mix (100 mg/ml penicillin, 100 mg/ml streptomycin, and 2 mg L-glutamine, GIBCO). HeLa cells were synchronised using a single thymidine block as described previously.
28 AR323 and AR678 were obtained from Dr Cheryl Napier (Array Biopharma, Boulder CO, USA).
Screening protocol
Optimal seeding densities were determined for each cell line in a 96-well format to ensure optimal growth conditions were maintained for the duration of the screening procedure. For screening, cells were seeded in 96-well plates at appropriate densities in triplicate wells. All cells were incubated in 100 ml of media for 24 h. Cells were then treated with two selective Chk1 inhibitors, AR323 and AR678, and compared with a dimethyl sulfoxide control. Treatments were administered over three logs of increasing concentrations, ranging from 0 to 3 mM. Cells were analysed at time points 0, 48 and 72 h (or 96 h in the case of slower-growing melanoma cell lines). The analysis involved performing a trilogy of assays measuring cell viability (resazurin assay) and cell death (adenylate kinase assay) in each well. For the adenylate kinase assay, 20 ml of supernatant from each well was transferred to a low-affinity binding, opaque, white 96-well assay plate. Equal volume (20 ml) of adenylate kinase reagent (Lonza) was added to the supernatant and the luminescence signal generated and quantitated after 30 min. For the resazurin assay, 44 mM resazurin was added to the cells in the remaining supernatant. Plates were incubated for 1.5 h and the fluorescence intensity quantitated (excitation 544 nm, emission 590 nm). The resazurin data were also used to determine cell sensitivity to the administered drugs by calculating the IC 50 (half-maximal inhibitory concentration) based on 72 or 96 h. Chk1 inhibitors target replicative stress K Brooks et al GACTGCTTCTTCAG-3 0 , 5 0 -GTTCAACAAACGCTCACGA-3 0 and 5 0 -TTATTATA CCGAAATACTG-3 0 , and in some experiments 25 nM Dharmacon Smart pool Chk1 siRNA was used using Dharmafect 2 as the transfection reagent (Thermo Scientific, Scoresby, Victoria, Australia). Cells were either synchronised after transfection using a thymidine block release, or fixed and stained for activated Chk1.
Flow cytometry
Fluorescence-activated cell sorting analysis of DNA content was performed as described previously 28 and analysed using FlowJo Flow Cytometry Analysis Software (TreeStar Inc., Ashland, OR, USA).
Immunoblotting
Cells were lysed in buffer (0.5% sodium dodecyl sulphate, 0.25 M NaCl, 0.25% protease inhibitor, 1 mM phenylmethanesulphonyl fluoride, 0.1 mM NaVO 4 , 25 mM NaF, 25 mM b-glycerophosphate), protein concentrations equalised and proteins resolved by sodium dodecyl sulfate --polyacrylamide gel electrophoresis. The proteins were transferred onto nitrocellulose membranes (Millipore, Kilsyth, Victoria, Australia) and probed with antibodies against poly(ADP-ribose) polymerase, pChk1 Ser317, pChk1 S296, Chk1, gH2AX, H3, pMEK1 T286, pChk1 Y15 (Cell Signalling Technology, Genesearch, Arundel, Queensland, Australia), cyclin B1 28 and p16, 39 and the appropriate horseradish peroxidase-conjugated secondary antibody. Antibody binding was detected using chemiluminescence. Membranes were stripped and re-probed with antibody against proliferating cell nuclear antigen (PCNA; Dako, Campbellfield, Victoria, Australia) or a-tubulin (Sigma Aldrich, Castle Hill, New South Wales, Australia) as a loading control.
Immunofluorescence
Cells were grown on sterile cover slips for 48 h and then treated with 1 mM AR323 or dimethyl sulfoxide as the diluent control. After drug treatment, cells were washed then fixed in À20 1C 100% methanol and stored at À20 1C until processing. Cells were washed in phosphate-buffered saline and rehydrated for 1 h in cell-blocking solution containing 3% bovine serum albumin and 0.1% saponin in phosphate-buffered saline before primary antibody addition. The cover slips were then incubated overnight in appropriate primary antibodies at 4 1C, then developed as described previously. 40 Immunofluorescence was imaged using a Zeiss Z1 epifluorescence microscope using 63 Â oil objectives and Axiovision software (Zeiss, North Ryde, New South Wales, Australia). Quantitative imaging was performed on cells grown in 96-well tissue culture plates (Viewplates, Perkin Elmer, Waltham, MA, USA) using the Cellomics ArrayScan (Thermo Scientific) automated epifluorescence microscope as described in Ranall et al. 41 Cells stained without the primary antibody were used to control for background staining. Only the level of the nuclear pChk1 S317 staining was quantitated as this was shown in the Chk1 siRNA depletion experiment to be the specific signal (Supplementary Figure S7A) .
Time-lapse microscopy
Cells were seeded into a 12-well plate and treated with 1 mM AR323 or dimethyl sulfoxide (control). Time-lapse images were produced using Zeiss Axiovert 200M Live Cell Imager with a 37 1C incubator and 5% CO 2 cover. Images were taken at 15-min intervals for 72 h, immediately following drug addition. The rate of mitotic entry for both normal and abnormal mitoses was quantified by visual inspection of mitotic cells, and was scored for normal and abnormal mitosis. The data are presented as cumulative mitotic scores. In all cases over 100 cells were counted. In a subset of experiments, cells were treated with 50 nM scrambled or Chk1 siRNA, and after 4 h synchronised overnight with 2.5 mM thymidine. Following incubation with thymidine, cells were released from the synchrony arrest and followed by time-lapse microscopy from 5 h post release. In these experiments, Chk1 inhibitor or dimethyl sulfoxide control was used in parallel and was added at 5 h post thymidine release.
